

Trial	Sponsor	ID	Intervention
ASPECCT – a study of panitumumab efficacy and safety compared with cetuximab in subjects with <i>KRAS</i> WT metastatic colorectal cancer	Amgen	NCT01001377	Experimental: panitumumab Comparator: cetuximab
Bevacizumab maintenance vs no maintenance after stop of first-line chemotherapy in patients with metastatic colorectal cancer. A randomised multicentre Phase III non-inferiority trial	Swiss Group for Clinical Cancer Research	NCT00544700	Experimental: bevacizumab maintenance therapy Comparator: no maintenance therapy
A prospective randomised open-label trial of oxaliplatin/ fluoropyrimidine vs oxaliplatin/fluoropyrimidine plus cetuximab pre- and postoperatively in patients with resectable colorectal liver metastasis requiring chemotherapy	Southampton University Hospitals NHS Trust	NCT00482222	Experimental: oxaliplatin/ fluoropyrimidine plus cetuximab Comparator: oxaliplatin/fluoropyrimidine
Phase III trial of irinotecan-based chemotherapy plus cetuximab (NSC-714682) with or without bevacizumab (NSC-704965) as second-line therapy for patients with metastatic colorectal cancer who have progressed on bevacizumab with FOLFOX, OPTIMO ^a or XELOX	Southwest Oncology Group	NCT00499369	Experimental: irinotecan or FOLFIRI and cetuximab plus bevacizumab Comparator: irinotecan or FOLFIRI plus cetuximab
SPIRITT – multicentre, open-label, randomised, Phase II clinical trial evaluating the safety and efficacy of FOLFIRI with either panitumumab or bevacizumab as second-line treatment in subjects with metastatic colorectal cancer with WT <i>KRAS</i> tumours	Amgen	NCT00418938	Experimental: FOLFIRI plus panitumumab Comparator: FOLFIRI plus bevacizumab
PICCOLO – a randomised clinical trial of treatment for fluorouracil-resistant advanced colorectal cancer comparing standard single-agent irinotecan with irinotecan plus panitumumab and irinotecan plus ciclosporin	University of Leeds CTAAC (UK), Amgen (UK)	NCT00389870	1. Irinotecan 2. Irinotecan with ciclosporin 3. Irinotecan plus panitumumab 4. Irinotecan with ciclosporin plus panitumumab
Study of irinotecan and cetuximab vs irinotecan as second-line treatment in patients with metastatic, EGFR-positive colorectal cancer	ImClone LLC, Bristol-Myers Squibb	NCT00063141	Experimental: cetuximab plus irinotecan Comparator: irinotecan
A study of R05083945 in combination with FOLFIRI vs FOLFIRI plus cetuximab or FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer	Hoffmann-La Roche	NCT01326000	<i>KRAS</i> WT A: experimental: R05083945 plus FOLFIRI <i>KRAS</i> WT B: comparator: FOLFIRI plus cetuximab <i>KRAS</i> mutant A: experimental: R05083945 plus FOLFIRI <i>KRAS</i> mutant B: comparator: FOLFIRI

CTAAC, Clinical Trials Advisory and Awards Committee; NCT, National Clinical Trials.

a A stop and go approach to administering oxaliplatin therapy before the development of resistance.